Frontiers in Clinical Drug Research - CNS and Neurological Disorders: Volume 10 E-Book
73,52 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Wissenschaft und neue Technologien
- Serie: Frontiers in Clinical Drug Research - CNS and Neurological Disorders
- Sprache: Englisch
Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.
Volume 10 of the series continues to present novel information about new and interesting approaches to treat common neurological disorders, with a focus on neurodegeneration and pain medicine. The volume presents 7 detailed reviews in total.
- Neurodegenerative disease: prevention and treatment through plant extracts therapy
- Emerging novel approaches and recent advances in Parkinson’s disease treatment and diagnosis
- Neurotrophic factors to combat neurodegeneration
- Neural bases of executive function in ADHD children as assessed using FNIRS
- Modulation of mesenchymal stem cells, glial cells and the immune system by oligodeoxynucleotides as a novel multi-target therapeutic approach against chronic pain
- Chronic pain: focus on anticonvulsants
- A review of the impact of testosterone on brain and aging-related decline in brain behavioural function
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 704
Veröffentlichungsjahr: 2001
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
PREFACE
Syuichi KoaradaNeurodegenerative and neurological disorders cost patients and societies trillions of dollars in terms of health care and out-of-pocket costs every year. This significant economical and neurodegenerative burden of brain disorders is expected to grow exponentially, especially in low- and middle-income countries in the next decade, if left unattended. There is a desperate need to focus our research strategies on epidemiology, disease frequency, and the understanding of the associated risk factors and possible outcomes to develop the therapeutics faster.
Volume 10 of our book series Frontiers in Clinical Drug Research - CNS and Neurological Disorders presents a set of creative and ground-breaking research endeavors of established as well as emerging researchers in the field. Our eminent authors have reviewed, evaluated, commented, and provided their valued feedback regarding the current central nervous system disorders to keep our readers updated.
For instance, Chapter 1 compares the potency of therapeutic preparations derived from medicinal plants with the currently available pharmaceutical treatments for Parkinson's, Alzheimer’s, and Huntington’s Diseases. The chapter specifically focuses on the active ingredients, molecular targets, and challenges to developing plant-based pharmaceuticals. Chapter 2 reviews the biochemical and physiological mechanism(s) of Parkinson's disease pathogenesis. The chapter also highlights the emerging therapies, such as stem cell progenitor cells transplantation, and the targeting of neurogenesis, apoptosis, neuroinflammation, mitochondrial dysfunction, and oxidative damage to treat Parkinson's disease. Chapter 3 summarizes the translational limitations of using neurotrophic factors in various preclinical and clinical trials to combat neurodegeneration and neuropathic pain in Parkinson’s disease. The author also discusses the current alternatives with improved translational perspectives, such as mutant proteins, small molecules, and peptides that target receptors for neurotrophic factors. Chapter 4 highlights the advantages of using functional near-infrared spectroscopy to explore the neural bases of executive functions in children suffering from attention deficit hyperactivity disorder. The authors also discuss the utility of the technique in managing the accessibility and tolerance of body motion while measuring the sensitive cortical oxyhemoglobin concentration changes associated with neuronal activation. Chapter 5 analyses the translational potential of a non-CpG, and non-coding oligodeoxynucleotide (IMT504) as an anti-nociceptive to treat chronic pain. The chapter describes the immunomodulating, and anti-inflammatory activities of the oligodeoxynucleotide, and explores its future potential as a multi-target pain medication. Chapter 6 reviews the application, efficacy, and development of current anticonvulsants in chronic pain management. Chapter 7 evaluates the behavioral, morphological, and nootropic effects of testosterone treatment on brain functioning. The chapter emphasizes the limitations of testosterone clinical application in mitigating aging-related cognitive decline.
In a nutshell, the current volume brings together another collection of exciting and cutting-edge research works of prominent scientists from all corners of the world. It is anticipated that the scholarly compendium of timely review articles will serve as the harbinger of new brain therapeutics in the near future.
We are grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Editorial Director Publications), and Ms. Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers.
List of Contributors
Neurodegenerative Disease: Prevention and Treatment Through Plant Extracts Therapy
Mayookha V.P1,2,Geetha V1,Moumita Das1,2,Suresh Kumar G.1,2,*Abstract
Neurodegenerative diseases such as Parkinson's, Alzheimer’s, Huntington’s etc. have their root in damaged nerve cells followed by the loss of their functions. Though the exact reason for different neurodegenerative diseases is still unknown, degradation and accumulation of proteins in neurons, oxidative stress, inflammation, defects in mitochondria, genetic mutation etc., are said to be the general factors that leads to this disease. The old ages are the worst affected group due to the rise in human life expectancies. Although there is no complete cure for this disease, some drug treatments have been found to be useful for reducing few of the physical or mental symptoms associated with neurodegenerative diseases. In fact, most neurodegenerative disorders show multiple symptoms;a promising result can be achieved only through the combination of different compounds like natural plant extracts which have many disease targets. Antioxidants are proven to have the capacity to act against the oxidative stress developed in the cells. So, antioxidant rich plant extracts can be utilized for the treatment of neurological related disorders. Several studies are being carried out on the effect of various plant extracts on the neurodegenerative disease prevention, management as well as treatment. This chapter will discuss the in vitro, in vivo and clinical studies conducted on the effect of various plant extracts for the treatment and prevention of different neurodegenerative disease conditions.
INTRODUCTION
Neurodegenerative diseases include various types of disorders which result from the damage of neurons followed by their functional loss. Since the last 10 years, not many drugs were introduced for the treatment of neurodegenerative disease. Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, frontotemporal dementia and the spinocerebellar ataxias are some
major neurodegenerative diseases. They show different pathophysiological conditions, where some leads to memory and cognitive damages, and others may disturb a person's locomotor as well as speech and breath functions. Among these, Alzheimer's disease (AD) is a chronic, age-dependent neurodegenerative disease which is the major cause of dementia in older individuals and in the Western world, it is on the fourth place for the cause of death. AD starts with brain atrophy, leading to gradual damage of CNS. Specific neurofibrillary tangles and neural plaques are observed in post mortem. Another neurodegenerative disorder affecting millions of the elderly population is Parkinson's disease (PD), with most cases arising after the age of fifty. The noticeable symptoms are movement disorders, including tremor, inflexibility, slow motion, and trouble while walking and in posture. Due to slow dysfunction of dopamine-generating neurons in the basal ganglia substantia nigra, a midbrain area, the motor symptoms of PD result in gradual loss of muscle co-ordination and balance. Later, there may be cognitive and behavioral difficulties, with dementia usually arising in the early stages of the disorder, while the most commonly observed symptom is depression. Sensory, sleep and mental disorders are other symptoms. A neurodegenerative genetic disorder that impacts muscle function and contributes to cognitive impairment and psychiatric disorders is Huntington's disease (HD). It is distinguished by irregular repetitive writhing movements called chorea. Although the physical symptoms of HD can occur from children to elder individuals at any age, the typical symptoms start between the ages of 35 and 44. Efficient therapies should be in immediate action, but only a profound understanding of the reasons and mechanisms of each disease can come with them. The chapter discusses various aspects of medicinal plants, their phytochemicals, along with traditional uses, important bioactivities, psychological and clinical proof on effectiveness and safety.This chapter also emphasises on the promising evidences through animal studies as well as clinical trials.
Alzheimer’s Disease (AD)
Dementia is an ailment in which there is an immense reduction of mental and cognitive capacities of an individual. The affected individual is unable to function independently due to memory loss as a consequence of disease progression. Several reversible or irreversible causes are responsible for dementia. The most common reversible causes include substance abuse, subdural hematoma, removable tumors, and central nervous system (CNS) disorders (Table 1). Irreversible causes of dementia are neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD).
Alzheimer’s disease (AD) is the most common form of dementia, mostly found in old age. This clinical disorder affects almost 5% population among the people over 65 years of age and 25% of the population over 80 years. AD is mainly characterised by impairment of cumulative memory (especially anterograde amnesia), aphasia, agnosia and also impairment of other higher cognitive functions and insight, and by various personality and behavioural/ neuropsychiatric characteristics. Alzheimer’s disease was first reported in the year 1907 by Alois Alzheimer. He has used one newly emerged histological method for staining to recognize the elements of neurofibrillary tangles in the brain tissue. This identification remarkably became [together with β-amyloid (Aβ) plaques] the pathological pioneer for diagnosing the disease in the post-mortem condition. The formation of plaques and tangles in the brain of an affected individual is recognized as the crucial characteristic feature of the Alzheimer’s disease condition. Progressive loss in the connectivity between the nerve cells (neurons) in the brain is another important characteristic of this disease. The main function of the neurons is the transmission of messages in different parts of the brain and from the brain to different parts of the body like muscles and different organs. Various complicated changes occuring in the brain contribute to the Alzheimer’s disease. Initial damage is seen in the hippocampus area of the brain that is mainly responsible for forming memories. As the neurons degenerate, auxiliary parts of the brain get affected. At the end stage of this disease condition, the damage becomes severe, leading to shrinkage of the brain tissues remarkably. Alzheimer’s disease and other forms of dementia mainly cause immense dysfunction of the brain leading to several neurodegenerative conditions like neuronal injury, synaptic failure and neuronal death. Neuro fibrillary tangles (NFT) and neurophil threads are the main pathological hallmarks of AD [1].
Various hypotheses have been proposed to establish the foundation of multi factorial syndrome on the basis of several causative aspects [1], such as cholinergic hypothesis, Aβ hypothesis, tau hypothesis and inflammation hypothesis [2]. In the past two decades Aβ hypotheses has been persuaded in the scientific community [3]. In recent times, several studies have emphasized the functional importance of Aβ oligomers in causing impairment of synapses and also suggested this as a fundamental signal that may damage the integrity of brain functions [3-6].
The amyloid cascade theory has hypothesized that amyloid precursor protein (APP) is cleaved subsequently by the enzymes α-secretase followed by β and γ-secretases, which lead to an imbalance in the synthesis and clearance of Aβ peptide [7]. This imbalance causes spontaneous aggregation of Aβ peptides into soluble oligomers and also amalgamate to form insoluble fibrils of beta-sheet conformation which are eventually deposited in diffuse senile plaques [3, 8].
The synergistic activities of both neurons and astrocytes raise the production of Aβ42 oligomers [5, 10]. It has been noticed that an increase in the production of Aβ42 oligomers gives rise to oxidative stress, enhanced hyper-phosphorylation which induces toxicity on the synapses and mitochondria [1, 2]. The increase in the formation of Aβ42 senile plaques enhances the activation of microglia [8], which consequently stimulates the production and release of pro-inflammatory cytokines, including IL-1β, TNF-α, and IFN-γ. Further, these cytokines give rise to the surrounding astrocyte-neuron producing an ample amount of Aβ42 oligomers, thus stimulating higher production of Aβ42 and also its dispersal. Oligodendroglia (OLGs) associated with neurons–astrocyte complex; Aβ oligomers also result in its destruction. In the brains of AD patients, aggregation of Aβ oligomers enhances neuronal and vascular degeneration [5]. It increases the oxidative stress to which OLGs are particularly susceptible. They have a low level of reduced glutathione (GSH) content and also a high concentration of iron as a result of decreased oxygen radicals scavenging ability [6]. It has also been observed that Aβ42 oligomers may lead to damage of cholesterol rich membranes, specifically found in OLGs and myelin [5].
Current Pharmaceutical Treatment
Various drugs which are (semi-) synthetic have been recognized worldwide for the treatment of different forms of dementia especially Alzheimer’s disease. Few most extensively used curatives for AD related dementia are- selective reversible acetylcholinesterase (AChE) inhibitor donepezil, the non-selective butyrylcholinetserase (BuChE) and AChE inhibitor rivastigmine, as well as the N-methyl-D-aspartate (NMDA) receptor antagonist memantine [10, 11]. Most prominent drugs approved for clinical use in AD are Memantine, Rivastigmine, Donepezil, etc. ( Table 2). FDA approved a combined drug donepezil-memantine in the year 2014 from the brand NamzaricR for treating moderate to severe AD affected people, who are recommended with clinically effective dose of 10mg/day donepezil hydrochloride [12]. There have been reports on various side effects when this combination of medicines are taken, such as muscle problems, slow heartbeat, fainting, increased stomach acid levels, nausea, vomiting and also seizures. Few of the studies also have suggested that the above mentioned drugs did not ameliorate the agitation condition among the patients who are severely affected [13, 14]. Therefore, an immense investigation on the natural ingredients with potential bioactives for treating different dementia conditions demands the attention of the scientific community.
Current Drug from Plant Origin Against Dementia
Galantamine is the only drug originated from plants, that is advised widely for treating mild-to-moderate AD and AD related dementia. It has been proven to be effective through many clinical trials. Galantamine is also known as galanthamine. It is an alkaloid (isoquinoline) synthesized from the plants that belong to Amaryllidaceae family. galantamine was first discovered by a Bulgarian Chemist D. Paskov and his team in the year of 1956. It was first separated from bulbs of Galanthus nivalis (common snowdrop). The efficacy of this drug is very prominent and also has been enlisted in the treatment guidelines for Alzheimer’s disease/dementia in USA and Europe. There are many countries worldwide who have approved this drug, including Canada, in the European Union (except for The Netherlands, under the name NivalinR in 2000), Japan, Korea, Mexico, Singapore, South Africa, Thailand, etc. The plant-derived galantamine is a well-established medicine for the treatment of dementia. The main mechanism of galantamine is to modulate the acetylcholine signaling and inhibition of oxidative damage. Galantamine affects the brain’s cholinergic system through its distinctive duplex mode of action. It inhibits the AChE enzyme reversibly by competitive inhibition. It also allosterically enhances the activity of the nicotinic acetylcholine receptor (nAChR) [15].
Galantamine has a protective role in mitochondrial dysfunction. The changes that may occur in morphology and the membrane potential of mitochondria (MMP) which is instigated by Aβ25/35 or hydrogen peroxide treatment, can be reversed by galantamine [16]. Oxidative stress is mainly developed by the toxic effect of reactive oxygen species (ROS). These are mainly produced in mitochondrial membrane during electron transport. The neuroprotection efficacy of galantamine is mainly through protecting the mitochondria and also inhibiting AChE activity, thus it helps in decreasing oxidative damage to cells [17]. P-glycoprotein is present in brain’s vascular endothelium. It is a well-known transporter which resists multiple drugs targeted for brain. It effectively prevents many drugs crossing blood brain barrier and efflux back into the blood stream [18]. Galantamine may reduce the potency of this protein and allow many other drugs co-administered with it to reach the brain more easily [18]. Neurotoxicity induced cognitive impairment has been reported in the rat model, which includes mitochondrial dysfunction, oxidative damage etc. Galantamine helps in reversing this condition by enhancing the neuro protective potency of rofecoxib (an anti-inflammatory COX-2 inhibitor) and caffeic acid (a plant derived phenol) [19]. In a similar way, galantamine increases the antioxidant efficacy of melatonin, a brain sleep hormone. It has been reported that galantamine treatment delayed the onset of various behavioral symptoms of dementia consistently like anxiety, euphoria, depression, irritability, delusions and unusual motor behavior [20].
Overview of Treatment Strategies Based on Medicinal Plants
Dementias are basically known to be complex diseases, as shown in modern research having several molecular mechanisms involved in the pathogenesis of the disease conditions. This multiple mechanisms approach evolved new strategies to treat these pathologies: treatment of dementia should have a holistic perspective, including several underlying molecular targets instead of focusing in any particular target (Fig. 1). Plant and plant extracts comprises of several bioactives that are hypothesized to target additively or synergistically on multiple molecular mechanisms [21] ( Table 3). Several herbal medicines have been utilized for a long time for treating dementia related neurodegenerative disorders. But unfortunately, bioactive components of these herbs are poorly narrated. Similarly, we still know very little about how these compounds interact with each other and with prescribed medicines [22]. The extensive research on these emerging issues will be crucial to find out therapeutic approaches that are devoid of harmful side effects.
Important Medicinal Plants Used for the Treatment of Neurodegenerative Disorders
The following medicinal plants have been extensively studied and experimented for the treatment of neurodegenerative disorders ( Table 4).
Ginkgo Biloba
Ginkgo biloba (Coniferae) is a well-known traditional Chinese medicine which has been mostly used in treating respiratory diseases. Traditionally it has been used in Iran for the improvement of memory loss related to irregularities in blood circulation. This herb has been studied extensively for its promising role in treating cognitive disorders [23]. It is utilized mainly for improving memory impairment along with the alleviation of dementia and Alzheimer’s disease condition [24]. The two major phytochemical components thought to be responsible for neuroprotective function of Gingko are: terpene lactones (ginkgolides and bilobalide) and flavonoids (flavonols and flavone glycosides) [25, 26]. Ginkgo leaf extract contains about 24% flavonoids and 6% terpene lactones [27]. The most widely investigated herbal medicines for the treatment of cognitive impairment include the Gb extract known as EGb761. Several clinical trials are done to explore the potential of this standardized Gb extract for treating Alzheimer’s disease condition and also AD related dementia [25].
Gb extract targets multiple mechanisms for maintaining brain functions including regulation of oxidative stress through its potential antioxidant activity [24, 28-30]. The role of the extract in neuroprotection via modulating oxidative stress is likely to be modulation of circulating glucocorticoid levels, Aβ aggregation, ion homeostasis and growth factors synthesis. Moreover, the role played by bioactives from Gingko is well accepted in the scientific community in maintaining mitochondrial function. Several in vitro studies have reported the protective role of Gingko constituents to maintain mitochondrial membrane potential (MMP) from various toxicants and oxidative stress [23]. Gingko extract can be beneficial in various aspects of mitochondrial morphology such as fission [31], swelling [32], and coupling [33]. It is also reported to interact with mitochondrial electron transport chains. It was fascinating to find that there was a significant improvement in the oxidative phosphorylation efficiency in cells overexpressing amyloid precursor protein (APP) than in control cells [34]. This indicates the effectiveness of Ginkgo extract, especially in AD therapy. EGb761 may prevent dysfunction of neurovascular unit known to be one of the pathologies associated with AD [35]. In summary, Ginkgo extract exhibits neuroprotective effect through its antioxidative and/or antiplatelet activities. Clinical studies confirm the effectiveness of Ginkgo extract for dementia treatment.
Panax Ginseng C.A. Meyer (Ginseng)
Panax ginseng (root powder) has been used in Oriental medicine since thousands of years for treating a variety of disorders including pragmatic utilization for the treatment of cerebrovascular disease. The dried root of this plant has been used traditionally as a medicine mainly in China and Korea. There are various species of Panax, including P. ginseng (Oriental ginseng), P. japonicus (Japanese ginseng), P. quinquefolius (American ginseng), P. trifolius, P. notoginseng (Burkill) and P. major [23]. Panax ginseng CA Meyer is the most often used and extensively researched species among the other varieties of ginseng. Few active components of this plant like Rg1, Rg3 and ginseng polysaccharides have been explored for their therapeutic potential [36, 37].Ginsenoside Rg3 has a backbone of steroid with aliphatic side chains, including carbohydrate part. Rg3 is mainly responsible for the neuroprotective potential of ginseng. Heat treatment of the roots of ginseng at high temperature produces Rg3 [38, 39]. The bioactive components of ginseng are reported to target few of the mechanisms related to dementia-like amyloid-β metabolism, oxidative stress, neuro-inflammation and acetylcholine signaling. However,the exact effectiveness of ginseng on dementia patients remain undefined.
Curcuminoids from Genus Curcuma
Around 80 species belong to the genus Curcuma (commonly termed as Turmeric) and is one of the largest genera from the Zingiberaceae family [23]. The major bioactive phytochemical of Curcuma genus is curcumin. Curcumin is well known as a traditional Indian medicine for its effectiveness in treating several disorders like anorexia, hepatic diseases, cold, cough and others. Curcumin has a great potential in neuroprotective actions through its various properties like antioxidant, anti-neuro-inflammatory, anti-proliferative, anti-amyloidogenic and neuro-regulative effects [39]. The major functions of Curcumin involve inhibiting the activity of tumor necrosis factor (TNF), preventing the formation of Aβ plaques and also protecting the brain cells from noxious agents [40]. Diets enriched with Curcumin strengthens memory and hippocampal neurogenesis in aged rats. Curcumin modulated expression of several genes are specifically involved in cell growth and synaptic plasticity [41]. The neuroprotective efficacy of curcumin is mainly because of its anti-inflammatory, antioxidant and lipophilic functions. In-vitro studies have shown that curcumin provides protection to mitochondria from several noxious factors like oxidative stress and rotenone (inhibitor of electron transport chain) [42, 43]. Various studies have shown that aging generally leads to mitochondrial loss and also diminished oxidative activity in rodent brains [44, 45]. Treatment with curcumin ameliorates this condition and also it has shown to improve the hippocampal-dependent memory of Aβ-infused rats [46].
Glycyrrhiza Species
Licorice (liquorice) belongs to the genus Glycyrrhiza, is a well-known member of Fabaceae family and comprises around 30 species. Many plants of this genus are enduring herbs originating from Mediterranean region, Asia, Southern Russia and Iran [47]. The licorice roots and also rhizomes are naturally sweet, so utilized all over the world as a sweetener. It has been traditionally used in herbal therapeutics because of its protective role, mainly in autoimmune hepatitis C, jaundice, peptic ulcer and skin diseases such as atopic dermatitis and inflammation induced hyperpigmentation [47, 48]; several studies have suggested the pharmacological importance of licorice roots in many disease conditions. Important properties include its anticancer, antioxidative, anti-inflammatory, antiviral, antimicrobial, hepatic and cardioprotective effects [47, 49].
The main bioactive phytochemical of Glycyrrhiza glabra (liquorice) root are - triterpene saponin glycyrrhizin (glycyrrhizic acid) and the phenolic type compound isoliquiritigenin. Other important ingredients also include several isoflavonoid derivatives such as shinpterocarpin, glabrone, glabridin, galbrene, lico-isoflavones A and B [47]. The active ingredients of licorice have potent antioxidant activities. Various species of Glycyrrhiza were studied and have been shown to possess neuroprotective ability, thus may help in treating neurodegenerative disorders such as PD, AD and dementia. The effectiveness of the extract of G. inflate was investigated in the cell model of spinocerebellar ataxia type 3 (SCA3) also known as Machado-Joseph disease (MJD) and results have shown to reduce oxidative stress through upregulation of PPARGC1A and the NFE2L2-ARE pathway [50]. MPP+ (1-methyl-4-phenylpyridinium) is a neurotoxic compound which is mainly involved in interfering mitochondrial oxidative phosphorylation [51]. This component arises several conditions like cytotoxicity, ROS generation and downregulation of glutathione (GSH). Glycyrrhizin is known to reverse these conditions induced by MPP+ [51]. Brain cells are prone to oxidative damage. Licorice extract mainly reduces the oxidative stress in the brain cells by acting on the mitochondrial function. The active compound is oliquiritigenin from licorice is known to be responsible for this activity [52]. Licorice also reverses the damage in the brain cells by improving the neuronal function, preventing the memory impairment connected to dementia condition. Apart from the antioxidative effect of licorice, it is also associated with anti-inflammatory properties known to enhance memory in dementia condition [23]. In summary, the extract of Glycyrrhiza is shown to possess anti-inflammatory and antioxidative properties and also has a modulating role in glutamate signaling and apoptosis.
Camellia Sinensis Kuntze
One of the most considerably consumed beverages worldwide includes Camellia sinensis Kuntze (green tea) brew [53]. It has been reported in animal as well as human studies that consuming green tea regularly helps in improving cognitive functions and also inhibits impairment of memory. The compound in green tea which is mainly responsible for these functions is-epigallocatechin-3-gallate. Consumption of green tea on a daily basis has been speculated to minimize the risk of developing age-related dementia and AD [54]. Some of the clinical studies have reported that L-theanine exhibited improvement in the cognitive functions and mood in amalgamation with caffeine in healthy human individuals, although, the results of few studies on the effects of L-theanine alone on mood remained elusive. Green tea catechins have the potential to modulate the activity of P-glycoprotein, thus influencing the easier availability of co-administered components to the brain. In summary, green tea extract showed antiapoptotic and antioxidative functions. It has the potential to inhibit Aβ plaque formation directly [23]. Various human studies incorporated the integrity to the hypothesis of the effectiveness of green tea in modulating human cognitive function and also its importance in treating dementia condition.
Moringa Oleifera
Moringa oleifera (MO) is included in the family Moringaceae. It is commonly found in almost everywhere in Asian and African countries. The fruit and leaves of Moringa oleifera have shown to possess anti-inflammatory and hypotensive effect and also consumed as a food ingredient by many people. It has been discovered recently that Moringa oleifera leaf extract is not toxic when taken even in higher concentration levels. It enhances memory through nootropics function and also delivers important antioxidants which includes vitamin C and E that helps in combating oxidative stress in AD. Several investigations have shown that the memory loss caused by monoamines is modified by leaf extracts of Moringa oleifera [55, 56]. Various lines of evidence also have shown that colchicines-induced AD can be altered by ethanolic extract of Moringa oleifera by modifying the brain monoamines (norepinephrine, dopamine and serotonin) and electrical activity in a rat model [55].
Parkinson’s Disease
Parkinson's disease (PD) is a multifactorial condition which is age-related and involves the neurodegeneration of dopaminergic neurons in substantia nigra, which is neuropathologically recognized. The nerve cells (neurons) in the brain gradually break down or die in Parkinson's disease. Many of the effects are due to the loss of neurons that forms - dopamine; a chemical messenger in the brain. It induces abnormal brain activity as dopamine levels decline, leading to impaired movement and other symptoms of Parkinson's disease.
In PD study, the development of symptomatic therapies has been partially successful, but a number of inadequacies remain in the therapeutic strategies for the disease. Symptoms of Parkinson's generally start out progressively and get worse over time. People can have trouble walking and talking as the disease progresses. They may also experience mental and behavioral changes, issues with sleep, depression, trouble with memory, and exhaustion. Parkinson's disease appears in both men and women. The disorder, however, affects about 50 percent more men than women.
The cause of Parkinson's disease is unclear, but it appears that many factors play a role, including:
Pathophysiology of PD
PD pathogenesis is a multifactorial mechanism in which complex reactions such as inflammation, neurotoxicity of glutamate, increased iron and nitric oxide levels, depletion of endogenous antioxidants, decreased development of neurotrophic factors, increased expression of apoptotic proteins and blood circulation dysfunction lead to neuronal degeneration. Pathologically, PD is the gradual depletion of dopaminergic neurons in the brain area of substantia nigra pars compacta. Intracytoplasmic protein inclusions called Lewy bodies (LBs) and dystrophic neurites (Lewy neurites) are present in PD patients' surviving neurons. Genetic factors such as alpha-synuclein or parkin gene mutations and environmental factors such as neurotoxic contaminants have also been suggested for the initiation of PD.
Oxidative stress in substantia nigra is suspected to play a major role in the loss of neurons that create dopamine (DA). The other characteristic histopathological finding is the presence of deposits called lewy bodies in the surviving neurons which is the characteristic deficiency of DA in the substantia nigra was observed in the brain of PD patients after post mortem. Abnormal protein folding in PD is characterized by about 80 percent loss of the neurotransmitter dopamine in the corpus striatum.and DA in the corpus striatum region of the brain. Also, PD results because of more than 50% dopaminergic (DA-ergic) loss of neurons in the substantia nigra pars compacta (SNpc) region of the brain. The causative mechanisms of PD also includes oxidative stress and inflammation. Postural dysfunction in PD patients is due to the massive and gradual death of dopaminergic neurons in the substantia nigra. The existence of intra-neuronal protein aggregates which are known as lewy bodies, indicates the cellular inability to clear abnormal proteins, is also one of the main pathological characteristics of the disease.
Dopamine is a dietary amino acid (tyrosine) neurotransmitter and has essential roles in a number of motor, cognitive, motivational, and neuroendocrine functions. The key class of medications used to treat PD symptoms are DA receptor agonists (e.g., bromocriptin, cabergoline, pergolide, rotigotine, apomorphine, ropinirole, and pamipexole). Due to the gradual loss of neuronal cells in the brain that synthesize it, PD symptoms arise in response to decreased levels of the chemical messenger DA. Increased levels of free radicals, oxidative stress, inflammation, mitochondrial dysfunction, and alpha-synuclein aggregation are the neurochemical events related to the pathology of PD. In addition, PD has also recorded increased concentrations of redox active metals such as iron and copper, decreased levels of glutathione and increased lipid peroxidation.
Pharmacological treatments currently available have only modest symptomatic relief for PD patients and have no success in reversing the underlying neuropathological changes associated with this disorder. There is also a clinical need to have therapeutic agents to recognize the agents that may enhance the deleterious processes associated with PD or slow them down. Relevant molecular or pharmacological effects, which are likely to contribute to the production of neuroprotective agents against PD, have been observed increasingly in natural products [78]. However, there is no complete understanding of the pathogenesis and etiology of PD. Important cellular causes of dopaminergic cell death, including neuroinflammation, oxidative stress, mitochondrial dysfunction and excitotoxicity have been outlined by comprehensive analysis of different models imitating key features of PD. Neurotoxic models have proven to be a valuable method for the development of new therapeutic strategies and also for the assessment of the effectiveness and adverse effects of PD symptomatic therapy.
Several natural plant-derived products have the ability to be used as PD treatment drugs. They have been shown to play roles that would have the desired effects, and some of these or their derivatives have been introduced into clinical use. In order to delay or reverse the underlying neuronal degeneration observed in PD, plant-derived natural products and their constituents have been shown to have an impact on the regulation of the levels of dopaminergic neurotransmission and motor function. The anti-PD effects of these natural products are due to their regulation ability to reduce reactive oxygen species and neuroinflammation, production of dopamine, excitotoxicity, metal homeostasis, mitochondrial function, and cellular signaling pathways, all of which are disrupted in the brain of PD patients are regulated by the plant derived extracts. (Fig. 3).
Fig. (3)) Effect of various plant extracts on PD.The aggregation or fibril formation of α-syn oligomers is inhibited by phytochemicals and plant extracts. They also direct the development of α-syn oligomer into its unstructured form and also facilitate non-toxic pathways and can therefore be useful drugs for PD and synucleinopathy. The key advantage of phytochemicals is their structural diversity, which provides knowledge for drug discovery and production. There are several groups of phytochemicals, including saponins, lignins, glycosides, carotenoids, etc.
Structurally-diverse and secondary plant nitrogen-containing metabolites are alkaloids that are defensive agents against neurodegenerative diseases. Plant bioactive derivatives such as flavonoids, stilbenoids and alkaloids have strong anti-oxidant and anti-inflammatory properties which are of great importance for PD treatment. These phytochemicals, which occur naturally, can also promote mitochondrial function and act as major cognitive enhancers. In addition, these compounds act as inhibitors of alpha- synuclein aggregation, activation of c-Jun N-terminal kinase (JNK) and development of monoamine oxidase (MAO) and are dopaminergic neuron agonists.
Ginsenosides: Ginsenosides are triterpinoid saponins unique to the species of Panax ginseng,eliciting a pleotrophic mode of action from these compounds. The inhibitory DA uptake activity of ginsenosides has the ability to act as antagonists for N-methyl-D-aspartate receptor (NMDA) and to defend neurons against mitochondrial dysfunction and elevation of glutamate and excitotoxicity caused by methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Ginsenoside's ability to minimize the influx of calcium and free radical generation and oxidative stress can also play a role in modifying the effects of ginseng in PD.
Caffeine: Caffeine is an antagonist for Adenosine 2A receptor present in the beans of Coffea arabica and Coffea canephora plants, which are widely distributed in Asia and Africa. In MPTP-induced PD mice, caffeine exerts neuroprotective effects against dopaminergic neuronal loss. In addition, caffeine in PD mouse models induces motor deficit reversal. It has been shown that the behavioral and neurobiochemical effects of caffeine cause a decrease in apomorphine-induced rotation and improved motor control. The amount of DA and its metabolites have also been shown to recover after administration of caffeine in the experimental depletion of dopaminergic neurotransmissions using neurotoxin 6-hydroxydopamine (6-OHDA).
Ginkgo biloba: Specific phytochemicals found only in the Ginkgo biloba tree are ginkgolides and bilobalides. In C57BL/6J mice, EGb761, a well-defined blend of active compounds extracted from the leaves, exerts a protective effect against MPTP-induced oxidative stress. In the striatum and substantia nigra pars compacta, mice receiving EGb761 recovered striatal DA levels and tyrosine hydroxylase. The neuroprotective effect of EGb761 against the neurotoxicity of MPTP is correlated with its free radical scavenging activity, lipid peroxidation blockage, and reduction of radical output of superoxides [79]. Additionally, G. biloba extract has an inhibitory effect on the activity of MAOs in rat mitochondria, indicating that its neuroprotective effects on dopaminergic neurons may be due to its inhibitory effects on monoamine oxidase.
Polygala: Polygala root extract (PRE) consists of xanthones, saponins and oligosaccharide esters [80] and has been documented to have a neuroprotective impact on dopaminergic neurons in both in vivo and in vitro PD models with 6-hydroxydopamine (6-OHDA) mediated neurotoxicity. The potential mechanism of action is due to decreased production of ROS and nitric oxide (NO) and altered activity of caspase-3 [81]. Furthermore, through binding to norepinephrine transporter proteins, oligosaccharide derivatives of PRE act against clinical depression. In addition, the 3,4,5-trimethoxycinnamic acid (TMCA) present in PRE exerts anti-stress effects by norepinephrine suppression.
Uncaria rhynchophylla: As a traditional medicine, Uncaria rhynchophylla is used to treat convulsive seizures, tremors, and hypertension. Rhynchophylline, corynoxeine, corynantheine, and hirsutine are the major alkaloids, with catechin and epicatechin being the main flavonoids. All animals with depleted DA activity using 6-OHDA have been shown to have a cytoprotective effect [82]. Dopaminergic neuronal loss and apomorphine mediated rotation were enhanced by Uncaria rhynchophylla extract (URE). In the meantime, a substantial decrease was observed in ROS and caspase 3 activity and a remarkable maintenance of cell viability and GSH levels was observed in PC12 neurotoxic cells.
Bacopa monniera:Bacopa monniera is a popular medicinal plant commonly used for the treatment of anxiety, memory disorders, and epilepsy. Bacopa moniera extract (BME) has been shown to exert a dose-dependent protective effect in 6-OHDA-lesioned PD rat models, as determined by major behavioral activity improvements and restoration of activity levels of GSH, SOD and catalase and decreased lipid peroxidation. Its antioxidant, free radical scavenging properties, and DA-enhancing effects are due to the potential mechanism of action of BME [83].
Cassia obtusifolia L:Cassia obtusifolia L, is an annual plant that is commonly consumed and widely distributed in Korea and China as roasted tea. In the substantia nigra and striatum of MPTP-induced PD mice and dopaminergic neurons in vitro, Cassiae semen (sicklepod) seed extract (CSE) has been shown to defend against dopaminergic neuronal degeneration. CSE supplementation has been shown to reduce cell damage and attenuate ROS generation and mitochondrial membrane depolarization in 6-OHDA mediated PC12 cells. MPP+, the neurotoxic metabolite of MPTP, causes neuronal dopaminergic loss by inhibiting respiratory complex 1 activity in dopaminergic neuron mitochondria [84].
The most abundant group of polyphenols with a well-established anti-parkinsonian effect are flavonoids. Citrus flavanone naringenin administration to rodents for four days prior to 6-OHDA injury resulted in a substantial decrease in the loss of tyrosine hydroxylase (TH)-positive cells as well as loss of DA and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the brain [85]. Since tyrosine hydroxylase catalyzes L-3,4-dihydroxyphenylalanine (L-DOPA) formation, which is the rate-limiting stage in dopamine biosynthesis, TH expression is one of the most widely used markers for the identification of DA neurons. The cellular mechanisms underlying the neuroprotective effects of naringenin have been studied and shown to activate the Keap1/Nrf2/ARE axis readily, thus inhibiting oxidative stress in mice with 6-OHDA lesions [86].
Pre-treatment with naringenin glycoside, naringin, has also been shown to provide neuroprotection in the PD experimental model [87]. By reducing neuro-inflammation and microglial activation as well as increasing the mammalian target of rapamycin complex 1 (mTORC1) activity, DA neurons in the mouse brain were protected.
The excitatory amino acid neurotransmitters and related receptors that are present in the CNS, such as the N-methyl-D-aspartate (NMDA) receptor, are gaining increasing attention. Natural products have been made that either bind to the receptors or influence the levels of the transmitters. The key therapeutic response to PD was to increase DA levels either by inhibiting monoamine oxidase (MAO), which metabolizes DA to compounds that are less active, or by increasing DA precursor concentrations by administering L-hydroxyphenylalanine (LDOPA). Strategic drug discovery that have advanced progress in the clinical treatment of PD patients have centered on the alleviation of motor symptoms by the use of dopaminergic mimetics, the development of novel nondopaminergic drugs for symptomatic improvement, and finally, the discovery of neuroprotective compounds with disease-modifying effects in PD.
There are cell lines of neuronal lineage that, when differentiated into dopaminergic neurons, have the potential to serve as a human cellular model for PD. Cell culture models have advantages over animal models since they can be based on human genomes, enabling pathophysiological characteristics to be directly investigated in far less time, less labor intensive, and these techniques can be developed for high-throughput screening of therapeutic compounds. The ability of transplantation of fetal dopaminergic cells to defend and restore the damaged nigrostriatal dopaminergic pathway has been studied by several researchers in clinical trials and in animal models [88]. The presynaptic protein alpha-Synuclein (α-syn) controls the release of neurotransmitters from the brain's synaptic vesicles. Like Lewy bodies, α-syn aggregates are features of both intermittent and familial PD forms.
Several major stages of fibrillation, aggregation and oligomerization have undergone by the aggregates. With disease development, therapeutic drug effects decrease and alleviate only symptomatic actions. Therefore, novel therapeutic techniques are required that can either inhibit or postpone the progression of PD. Literature illustrates the close link between α-syn and etiopathogenesis and PD progression. Studies show that α-syn is a significant therapeutic target and an important method of disease modification is the inhibition of its aggregation, oligomerization, and fibrillation. Several hypotheses for the death of dopaminergic cells in the SN compact and mitochondrial complex defect associated with the electron transport chain defect have been proposed [89].
Accumulating evidences indicate that the function of the mitochondrial complex I decreases partially in PD. Approximately 100 percent of molecular oxygen is consumed during cellular respiration by the mitochondria, and strong oxidants are formed as a by-product, including hydrogen peroxide and superoxide radicals. By inhibiting the mitochondrial complex I, which can generate toxic hydroxyl radicals or react with nitric oxide and produce peroxynitrites, and reactive oxygen species (ROS) production also increases. These molecules can also damage nucleic acids, proteins and lipids. A lot of research has also shown that ROS plays a part in the degeneration of dopaminergic neurons in PD patients' brain tissues. In the brain tissue of patients with PD, elevated levels of lipid peroxidation, glutathione depletion and increased protein oxidation are reported. Dopamine oxidation contributes to the formation of dopamine quinone, which is able to modify proteins directly.
